Targeted Oncology

Aims & Scope

Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology.

The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.

Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.

Current Opinion articles that place interesting areas in perspective.

Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.

Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.

Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4
2024	4.40

SJR (SCImago Journal Rank)

Year	Value
2024	1.645

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	63

Journal Rank

Year	Value
2024	2051

Journal Citation Indicator

Year	Value
2024	850

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside

  Citation: 432

  Authors: Margherita, Andrea, Michele, Massimiliano, Milko B., Nicola, Jens C.

• An Overview of PARP Inhibitors for the Treatment of Breast Cancer

  Citation: 311

  Authors: Laura, Hope S., Christian

• Sorafenib: A Review in Hepatocellular Carcinoma

  Citation: 250

  Authors: Gillian M.

• Hyperbaric oxygen therapy and cancer—a review

  Citation: 234

  Authors: Ingrid, Linda E. B.

• Skin toxicities associated with epidermal growth factor receptor inhibitors

  Citation: 216

  Authors: Tianhong, Roman

• Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

  Citation: 186

  Authors: Irene, Antonio, Patricia M., Lorrin K., Thomas A., Shobha, Bob, Carla J., Josep, Emiliano

• Vaccine Therapies for Cancer: Then and Now

  Citation: 183

  Authors: Michael A., William R., Duane A.

• Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis

  Citation: 150

  Authors: Roberto, Franco, Elena, Giuseppe, Chiara, Matteo, Maria, Palma, Gaetano, Daniela, Stefano, Camillo

• Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations

  Citation: 142

  Authors: Mehran, Edouard, Jonathan W., F. Meiring, Michael E., Sam, Eva R., Robert W., Kevin D., Olivier, Jeffrey P.

• Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

  Citation: 138

  Authors: Lee S., Ira A., Ronald L.

---